Ionis Pharmaceuticals, Inc. (IONS) Operating Margin
- Operating margin · 12 months: Value -68.00%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -68.00% | Operating income / revenue. Period ending 2026-06-30. $-594.35M ÷ $874.09M × 100 ≈ -68.00% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -594.35M USD | Operating Income (Loss) |
| Revenue | 874.09M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 16.02M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 527.75M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-594.35M | $874.09M | $16.02M | (m) | $527.75M | -68.00% |
| 2026-03-31 | $-352.25M | $1.06B | $17.43M | (m) | $467.98M | -33.29% |
| 2025-12-31 | $-381.68M | $943.71M | $15.91M | $915.62M | $393.87M | -40.45% |
| 2025-09-30 | $-278.05M | $966.96M | $11.78M | (m) | $351.76M | -28.75% |
| 2025-06-30 | $-266.52M | $944.05M | $10.52M | (m) | $316.59M | -28.23% |
| 2025-03-31 | $-472.43M | $717.25M | $10.53M | (m) | $291.08M | -65.87% |
| 2024-12-31 | $-475.08M | $705.14M | $11.21M | (m) | $267.47M | -67.37% |
| 2024-09-30 | $-370.38M | $803.07M | $10.45M | (m) | $250.41M | -46.12% |
| 2024-06-30 | $-364.99M | $813.46M | $11.57M | (m) | $258.72M | -44.87% |
| 2024-03-31 | $-389.10M | $776.62M | $9.94M | (m) | $239.75M | -50.10% |
| 2023-12-31 | $-353.73M | $787.65M | $9.13M | (m) | $232.62M | -44.91% |
| 2023-09-30 | $-555.63M | $615.03M | $9.76M | (m) | $209.56M | -90.34% |
| 2023-06-30 | $-471.52M | $630.59M | $9.08M | (m) | $174.02M | -74.77% |
| 2023-03-31 | $-466.83M | $575.97M | $11.29M | (m) | $161.68M | -81.05% |
| 2022-12-31 | $-410.19M | $587.37M | $14.12M | (m) | $150.29M | -69.84% |
| 2022-09-30 | $18.43M | $875.48M | $12.66M | (m) | $139.94M | 2.11% |
| 2022-06-30 | $-8.26M | $848.81M | $14.22M | (m) | $136.62M | -0.97% |
| 2022-03-31 | $4.28M | $840.77M | $12.43M | (m) | $159.28M | 0.51% |
| 2021-12-31 | $-30.19M | $810.46M | $10.84M | $638.20M | $186.35M | -3.72% |
| 2021-09-30 | $-273.46M | $660.73M | $11.92M | (m) | $287.61M | -41.39% |
| 2021-06-30 | $-224.14M | $687.72M | $11.92M | (m) | $324.97M | -32.59% |
| 2021-03-31 | $-202.93M | $707.50M | $11.98M | (m) | $340.53M | -28.68% |
| 2020-12-31 | $-172.08M | $729.26M | $11.95M | $531.00M | $354.32M | -23.60% |
| 2020-09-30 | $111.24M | $932.66M | $9.66M | (m) | $298.73M | 11.93% |
| 2020-06-30 | $150.30M | $940.48M | $7.54M | (m) | $290.32M | 15.98% |
| 2020-03-31 | $183.22M | $958.75M | $5.89M | (m) | $293.42M | 19.11% |
| 2019-12-31 | $365.88M | $1.12B | $4.38M | $461.50M | $286.64M | 32.59% |
| 2019-09-30 | $116.01M | $821.03M | $5.19M | (m) | $269.43M | 14.13% |
| 2019-06-30 | $94.92M | $798.53M | $4.23M | (m) | $278.10M | 11.89% |
| 2019-03-31 | $63.46M | $752.47M | $2.86M | (m) | $269.19M | 8.43% |
| 2018-12-31 | $-61.37M | $599.67M | $1.82M | $411.90M | $244.62M | -10.23% |
| 2018-09-30 | $-84.87M | $568.84M | (m) | (m) | $224.27M | -14.92% |
| 2018-06-30 | $-54.98M | $541.76M | (m) | (m) | $182.34M | -10.15% |
| 2018-03-31 | $1.75M | $536.28M | (m) | (m) | $138.46M | 0.33% |
| 2017-12-31 | $24.53M | $507.67M | (m) | $372.50M | $108.49M | 4.83% |
| 2017-09-30 | $67.38M | $495.71M | (m) | (m) | (m) | 13.59% |
| 2017-06-30 | $69.58M | $485.73M | (m) | (m) | (m) | 14.32% |
| 2017-03-31 | $22.32M | $420.05M | (m) | (m) | (m) | 5.31% |
| 2016-12-31 | $-46.32M | $346.62M | (m) | $340.40M | (m) | -13.36% |
| 2016-09-30 | $-150.41M | $237.84M | (m) | (m) | (m) | -63.24% |
| 2016-06-30 | $-214.66M | $176.04M | (m) | (m) | (m) | -121.94% |
| 2016-03-31 | $-121.08M | $257.99M | (m) | (m) | (m) | -46.93% |
| 2015-12-31 | $-75.76M | $283.70M | (m) | $319.50M | (m) | -26.70% |
| 2015-09-30 | $-2.74M | $316.99M | (m) | (m) | (m) | -0.86% |
| 2015-06-30 | $23.90M | $311.94M | (m) | (m) | (m) | 7.66% |
| 2015-05-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-27.39M | $248.58M | (m) | (m) | (m) | -11.02% |
| 2014-12-31 | $-47.73M | $214.16M | (m) | $238.90M | (m) | -22.29% |
| 2014-09-30 | $-77.67M | $171.55M | (m) | (m) | (m) | -45.28% |
| 2014-06-30 | $-81.68M | $151.07M | (m) | (m) | (m) | -54.07% |
| 2014-03-31 | $-82.96M | $132.09M | (m) | (m) | (m) | -62.81% |
| 2013-12-31 | $-51.67M | $147.28M | (m) | $173.70M | (m) | -35.08% |
| 2013-09-30 | $-57.93M | $124.91M | (m) | $167.86M | (m) | -46.38% |
| 2013-06-30 | $-60.47M | $112.92M | (m) | $160.25M | (m) | -53.55% |
| 2013-03-31 | $-48.84M | $122.17M | (m) | $158.06M | (m) | -39.98% |
| 2012-12-31 | $-68.92M | $102.05M | (m) | $158.46M | (m) | -67.54% |
| 2012-09-30 | $-61.42M | $114.58M | (m) | $162.92M | (m) | -53.61% |
| 2012-06-30 | $-55.69M | $123.69M | (m) | $166.29M | (m) | -45.02% |
| 2012-03-31 | $-73.45M | $101.17M | (m) | $161.87M | (m) | -72.59% |
| 2011-12-31 | $-71.10M | $99.09M | (m) | $157.40M | (m) | -71.76% |
| 2011-09-30 | $-68.34M | $93.10M | (m) | $149.51M | (m) | -73.40% |
| 2011-06-30 | $-54.97M | $101.01M | (m) | $144.30M | (m) | -54.42% |
| 2011-03-31 | $-59.58M | $99.69M | (m) | $147.42M | (m) | -59.77% |
| 2010-12-31 | $-48.36M | $108.47M | (m) | $145.16M | (m) | -44.58% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-27.54M | $121.60M | (m) | $134.62M | (m) | -22.65% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $-13.06M | $107.19M | (m) | $106.44M | (m) | -12.18% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |